NDA 021260 · King Pharms LLC
Avinza
Morphine Sulfate · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jun 26, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Mar 20, 2002
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2,053
400 Phase 3, 129 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 20, 2002 Original approval · Type 3 - New Dosage Form ReviewMedication GuideLetter
6 products under this application
- AVINZA · MORPHINE SULFATE 45MG · CAPSULE, EXTENDED RELEASE, ORAL · Discontinued
- AVINZA · MORPHINE SULFATE 90MG · CAPSULE, EXTENDED RELEASE, ORAL · Discontinued
- AVINZA · MORPHINE SULFATE 30MG · CAPSULE, EXTENDED RELEASE, ORAL · Discontinued
- AVINZA · MORPHINE SULFATE 75MG · CAPSULE, EXTENDED RELEASE, ORAL · Discontinued
- AVINZA · MORPHINE SULFATE 120MG · CAPSULE, EXTENDED RELEASE, ORAL · Discontinued
- AVINZA · MORPHINE SULFATE 60MG · CAPSULE, EXTENDED RELEASE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Morphine" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Opioid Prescription After Cesarean TrialPivotal-lookingCompleted
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT04296396 · 5,521 participants · Start Sep 21, 2020 · Primary completion Apr 7, 2022
Drug: 0 to 20 tablets of oxycodone 5mg; Fixed opioid prescription · For: Pregnancy Related; Opioid Use; Pain
Sites: Birmingham, Alabama; Chicago, Illinois; New York, New York · 12 sites in all
- Patient-controlled Intravenous Analgesia Combined With Different Opioid Receptors for Gastrointestinal SurgeryPivotal-lookingCompleted
Xijing HospitalAcademic, hospital or other
NCT05576675 · 4,342 participants · Start May 1, 2018 · Primary completion Mar 31, 2022
Drug: sufentanil + nalbuphine; Sufentanil and 1 more · For: Gastrointestinal Surgery
Sites: XIan, China
- A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02145468 · 3,503 participants · Start Jun 3, 2014 · Primary completion Dec 14, 2015
Drug: Losmapimod 7.5 mg twice daily; Placebo twice daily and 1 more · For: Acute Coronary Syndrome
Sites: Huntsville, Alabama; Cottonwood, Arizona; Tucson, Arizona · 341 sites in all
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated DataPivotal-lookingCompleted
Jennifer Holder-MurrayAcademic, hospital or other
NCT04606264 · 3,395 participants · Start May 15, 2023 · Primary completion Mar 21, 2025
Drug: Neuraxial Analgesia; Regional Block 1: Paravertebral and 6 more · For: Perioperative Optimization
Sites: Pittsburgh, Pennsylvania · 3 sites in all
- Stellate Ganglion Morphine Infiltration on Myocardial I/R InjuryPivotal-lookingRecruiting
The Second Hospital of Anhui Medical UniversityAcademic, hospital or other
NCT07023679 · 2,588 participants (planned) · Start Jun 24, 2025 · Primary completion Jun 20, 2029
Drug: Morphine; saline placebo · For: Acute Myocardial Infarction (AMI)
Sites: Hefei, China · 2 sites in all
- A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.Pivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06372145 · 2,500 participants (planned) · Start Apr 16, 2024 · Primary completion Apr 30, 2029
Drug: Tolebrutinib; Placebo and 1 more · For: Relapsing Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Progressive Relapsing Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 352 sites in all
- A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple SclerosisPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT02576717 · 2,494 participants · Start Oct 16, 2015 · Primary completion Jan 5, 2023
Drug: RPC1063 · For: Multiple Sclerosis
Sites: Phoenix, Arizona; Berkeley, California; Fresno, California · 175 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The analgesic effects of novel fascial plane blocks compared with intrathecal morphine after Caesarean delivery: a systematic review and meta-analysis.
Hussain N, Brull R, Thaete L, et al. · Br J Anaesth 2025 · Comparative Study, Meta-Analysis
- Effectiveness and Safety of Hydromorphone Compared to Morphine for Postoperative Analgesia: A Systematic Review and Meta-analysis.
Li Y, Yue X, Liang S, et al. · Pain Physician 2024 · Systematic Review, Meta-Analysis
- Oral tapentadol for cancer pain.
Wiffen PJ, Derry S, Naessens K, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Substance use and spine density: a systematic review and meta-analysis of preclinical studies.
Oliva HNP, Prudente TP, Nunes EJ, et al. · Mol Psychiatry 2024 · Systematic Review, Meta-Analysis
- Transversus abdominis plane block for postoperative pain management and opioid sparing: a systematic review and meta-analysis of randomised controlled trials.
Zako J, Kevorkov A, Jeffries SD, et al. · Br J Anaesth 2026 · Systematic Review, Meta-Analysis
- Sublingual Versus Swallowed Morphine: A Comparison.
Dyal BW, Powell-Roach KL, Robison J, et al. · Cancer Nurs 2021 · Comparative Study, Randomized Controlled Trial
Sponsor: King Pharms LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.